Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)

被引:461
作者
Barbui, Tiziano [1 ]
Finazzi, Guido [1 ]
Carobbio, Alessandra [1 ]
Thiele, Juergen [2 ]
Passamonti, Francesco [3 ,4 ]
Rumi, Elisa [5 ]
Ruggeri, Marco [6 ]
Rodeghiero, Francesco [6 ]
Randi, Maria Luigia [7 ]
Bertozzi, Irene [7 ]
Gisslinger, Heinz [8 ]
Buxhofer-Ausch, Veronika [8 ]
De Stefano, Valerio [9 ]
Betti, Silvia [9 ]
Rambaldi, Alessandro [1 ]
Vannucchi, Alessandro M. [10 ]
Tefferi, Ayalew [11 ]
机构
[1] Osped Riuniti Bergamo, I-24128 Bergamo, Italy
[2] Univ Cologne, D-50931 Cologne, Germany
[3] Univ Hosp Osped Circolo, Varese, Italy
[4] Fdn Macchi, Varese, Italy
[5] Univ Pavia, Policlin San Matteo, Ist Ricovero & Cura Carattere Sci, I-27100 Pavia, Italy
[6] San Bortolo Hosp, Vicenza, Italy
[7] Univ Padua, Padua, Italy
[8] Med Univ Vienna, Vienna, Austria
[9] Policlin Univ A Gemelli, Rome, Italy
[10] Univ Florence, Florence, Italy
[11] Mayo Clin, Rochester, MN USA
关键词
JAK2 V617F MUTATION; TYROSINE KINASE JAK2; POLYCYTHEMIA-VERA; RISK STRATIFICATION; LEUKOCYTOSIS; SURVIVAL; MANAGEMENT; ARTERIAL;
D O I
10.1182/blood-2012-07-444067
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Accurate prediction of thrombosis in essential thrombocythemia (ET) provides the platform for prospective studies exploring preventive measures. Current risk stratification for thrombosis in ET is 2-tiered and considers low-and high-risk categories based on the respective absence or presence of either age > 60 years or history of thrombosis. In an international study of 891 patients with World Health Organization (WHO)-defined ET, we identified additional independent risk factors including cardiovascular risk factors and JAK2V617F. Accordingly, we assigned risk scores based on multivariable analysis-derived hazard ratios (HRs) to age > 60 years (HR = 1.5; 1 point), thrombosis history (HR = 1.9; 2 points), cardiovascular risk factors (HR = 1.6; 1 point), and JAK2V617F (HR = 2.0; 2 points) and subsequently devised a 3-tiered prognostic model (low-risk = < 2 points; intermediate-risk = 2 points; and high-risk = > 2 points) using a training set of 535 patients and validated the results in the remaining cohort (n = 356; internal validation set) and in an external validation set (n = 329). Considering all 3 cohorts (n = 1220), the 3-tiered new prognostic model (low-risk n = 474 vs intermediate-risk n = 471 vs high-risk n = 275), with a respective thrombosis risk of 1.03% of patients/y versus 2.35% of patients/y versus 3.56% of patients/y, outperformed the 2-tiered (low-risk 0.95% of patients/y vs high-risk 2.86% of patients/y) conventional risk stratification in predicting future vascular events. (Blood. 2012; 120(26): 5128-5133)
引用
收藏
页码:5128 / 5133
页数:6
相关论文
共 28 条
[1]   Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia [J].
Alvarez-Larran, Alberto ;
Cervantes, Francisco ;
Pereira, Arturo ;
Arellano-Rodrigo, Eduardo ;
Perez-Andreu, Virginia ;
Hernandez-Boluda, Juan-Carlos ;
Ayats, Ramon ;
Salvador, Carlos ;
Muntanola, Ana ;
Bellosillo, Beatriz ;
Vicente, Vicente ;
Hernandez-Nieto, Luis ;
Burgaleta, Carmen ;
Xicoy, Blanca ;
Besses, Carlos .
BLOOD, 2010, 116 (08) :1205-1210
[2]   Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study [J].
Barbui, Tiziano ;
Thiele, Juergen ;
Passamonti, Francesco ;
Rumi, Elisa ;
Boveri, Emanuela ;
Ruggeri, Marco ;
Rodeghiero, Francesco ;
d'Amore, Emanuele S. G. ;
Randi, Maria Luigia ;
Bertozzi, Irene ;
Marino, Filippo ;
Vannucchi, Alessandro M. ;
Antonioli, Elisabetta ;
Carrai, Valentina ;
Gisslinger, Heinz ;
Buxhofer-Ausch, Veronika ;
Muellauer, Leonhard ;
Carobbio, Alessandra ;
Gianatti, Andrea ;
Gangat, Naseema ;
Hanson, Curtis A. ;
Tefferi, Ayalew .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (23) :3179-3184
[3]   Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet [J].
Barbui, Tiziano ;
Barosi, Giovanni ;
Birgegard, Gunnar ;
Cervantes, Francisco ;
Finazzi, Guido ;
Griesshammer, Martin ;
Harrison, Claire ;
Hasselbalch, Hans Carl ;
Hehlmann, Rudiger ;
Hoffman, Ronald ;
Kiladjian, Jean-Jacques ;
Kroeger, Nicolaus ;
Mesa, Ruben ;
McMullin, Mary F. ;
Pardanani, Animesh ;
Passamonti, Francesco ;
Vannucchi, Alessandro M. ;
Reiter, Andreas ;
Silver, Richard T. ;
Verstovsek, Srdan ;
Tefferi, Ayalew .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (06) :761-770
[4]   Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? [J].
Barbui, Tiziano ;
Carobbio, Alessandra ;
Rambaldi, Alessandro ;
Finazzi, Guido .
BLOOD, 2009, 114 (04) :759-763
[5]   Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [J].
Baxter, EJ ;
Scott, LM ;
Campbell, PJ ;
East, C ;
Fourouclas, N ;
Swanton, S ;
Vassiliou, GS ;
Bench, AJ ;
Boyd, EM ;
Curtin, N ;
Scott, MA ;
Erber, WN ;
Green, AR .
LANCET, 2005, 365 (9464) :1054-1061
[6]   Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: An international study of 264 patients [J].
Buxhofer-Ausch, Veronika ;
Gisslinger, Heinz ;
Thiele, Juergen ;
Gisslinger, Bettina ;
Kvasnicka, Hans-Michael ;
Muellauer, Leonhard ;
Frantal, Sophie ;
Carobbio, Alessandra ;
Passamonti, Francesco ;
Rumi, Elisa ;
Ruggeri, Marco ;
Rodeghiero, Francesco ;
Randi, Maria L. ;
Bertozzi, Irene ;
Vannucchi, Alessandro M. ;
Antonioli, Elisabetta ;
Finazzi, Guido ;
Gangat, Naseema ;
Tefferi, Ayalew ;
Barbui, Tiziano .
AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (07) :669-672
[7]   Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status:: a prospective study [J].
Campbell, PJ ;
Scott, LM ;
Buck, G ;
Wheatley, K ;
East, CL ;
Marsden, JT ;
Duffy, A ;
Boyd, EM ;
Bench, AJ ;
Scott, MA ;
Vassiliou, GS ;
Milligan, DW ;
Smith, SR ;
Erber, WN ;
Bareford, D ;
Wilkins, BS ;
Reilly, JT ;
Harrison, CN ;
Green, AR .
LANCET, 2005, 366 (9501) :1945-1953
[8]   Leukocytosis and risk stratification assessment in essential thrombocythemia [J].
Carobbio, Alessandra ;
Antonioli, Elisabetta ;
Guglielmelli, Paola ;
Vannucchi, Alessandro M. ;
Delaini, Federica ;
Guerini, Vittoria ;
Finazzi, Guido ;
Rambaldi, Alessandro ;
Barbui, Tiziano .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (16) :2732-2736
[9]   Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status [J].
Carobbio, Alessandra ;
Finazzi, Guido ;
Guerini, Vittoria ;
Spinelli, Orietta ;
Delaini, Federica ;
Marchioli, Roberto ;
Borrelli, Giovanna ;
Rambaldi, Alessandro ;
Barbui, Tiziano .
BLOOD, 2007, 109 (06) :2310-2313
[10]   Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients [J].
Carobbio, Alessandra ;
Thiele, Juergen ;
Passamonti, Francesco ;
Rumi, Elisa ;
Ruggeri, Marco ;
Rodeghiero, Francesco ;
Randi, Maria Luigia ;
Bertozzi, Irene ;
Vannucchi, Alessandro M. ;
Antonioli, Elisabetta ;
Gisslinger, Heinz ;
Buxhofer-Ausch, Veronika ;
Finazzi, Guido ;
Gangat, Naseema ;
Tefferi, Ayalew ;
Barbui, Tiziano .
BLOOD, 2011, 117 (22) :5857-5859